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Introduction  
This guideline makes recommendations for the use of psychosocial 
interventions in the treatment of people who misuse opioids, stimulants and 
cannabis in the healthcare and criminal justice systems. The patterns of use 
vary for these drugs, with cannabis the most likely to be used in the UK. 
Cocaine is the next most commonly used drug in the UK, followed by other 
stimulants such as amphetamine. Opioids, although presenting the most 
significant health problem, are used less commonly. A large proportion of 
people who misuse drugs are polydrug users and do not limit their use to one 
particular drug. This guideline will not deal with recreational drug use, 
although opportunistic brief interventions for people who misuse drugs but 
who are not in formal drug treatment are included. The guideline also does not 
specifically address drug misuse in pregnancy. 
Opioid misuse is often characterised as a long-term, chronic condition with 
periods of remission and relapse. Although abstinence may be one of the 
long-term goals of treatment, it is not always achieved. The patterns of 
cannabis and stimulant misuse vary considerably and are less well 
understood. 
Pharmacological approaches are the primary treatment option for opioid 
misuse, with psychosocial interventions providing an important element of the 
overall treatment package. Pharmacological treatments for cannabis and 
stimulant misuse are not well developed, and therefore psychosocial 
interventions are the mainstay of effective treatment.  
In order to ensure that all people to whom this guidance applies obtain full 
benefit from the recommendations, it is important that effective keyworking 
systems are in place. Keyworking is an important element of care and helps to 
deliver high-quality outcomes for people who misuse drugs. Keyworkers have 
a central role in coordinating a care plan and building a therapeutic alliance 
with the service user. The benefits of a number of the recommendations in 
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 this guideline will only be fully realised in the context of properly coordinated 
care. 
NICE has also developed a clinical guideline on opioid detoxification for drug 
misuse, public health intervention guidance on substance misuse in children 
and young people, and technology appraisals of methadone/buprenorphine 
and naltrexone for the management of opioid dependence (see section 6 
below). 
This guideline should be read in conjunction with the forthcoming publication 
‘Drug misuse and dependence – guidelines on clinical management: update 
2007’, also known as the ‘Orange Book’, which provides advice to healthcare 
professionals on the delivery and implementation of a broad range of 
interventions for drug misuse, including those interventions covered in the 
present guideline. For more information visit www.nta.nhs.uk. 
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Person-centred care 
This guideline offers best-practice advice on the care of people who misuse 
drugs.  
Treatment and care should take into account service users’ needs and 
preferences. People who misuse drugs should have the opportunity to make 
informed decisions about their care and treatment, in partnership with their 
healthcare professionals. If service users do not have the capacity to make 
decisions, staff should follow the Department of Health guidelines – 
‘Reference guide to consent for examination or treatment’ (2001) (available 
from www.dh.gov.uk). Since April 2007 staff need to follow a code of practice 
accompanying the Mental Capacity Act (summary available from 
www.dca.gov.uk/menincap/bill-summary.htm). 
Good communication between staff and service users is essential. It should 
be supported by evidence-based written information tailored to the service 
user’s needs. Treatment and care, and the information service users are given 
about it, should be culturally appropriate. It should also be accessible to 
people with additional needs, such as physical, sensory or learning 
disabilities, and to people who do not speak or read English. 
If the service user agrees, families and carers should have the opportunity to 
be involved in decisions about treatment and care. Families and carers should 
also be given the information and support they need.  
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Key priorities for implementation 
Brief interventions  
Opportunistic brief interventions focused on motivation should be offered to 
people in limited contact with drug services (for example, those attending a 
needle and syringe exchange or primary care settings) if concerns about drug 
misuse are identified by the service user or staff member. These interventions 
should: 
• normally consist of two sessions each lasting 10–45 minutes  
• explore ambivalence about drug use and possible treatment, with the aim 
of increasing motivation to change behaviour, and provide non-judgemental 
feedback.  
 
Self-help 
Staff should routinely provide people who misuse drugs with information about 
self-help groups. These groups should normally be based on 12-step 
principles; for example, Narcotics Anonymous and Cocaine Anonymous.  
Contingency management 
Introducing contingency management 
Drug services should introduce contingency management programmes – as 
part of the phased implementation programme led by the National Treatment 
Agency for Substance Misuse (NTA) – to reduce illicit drug use and/or 
promote engagement with services for people receiving methadone 
maintenance treatment.  
Principles of contingency management 
Contingency management aimed at reducing illicit drug use for people 
receiving methadone maintenance treatment or who primarily misuse 
stimulants should be based on the following principles: 
• The programme should offer incentives (usually vouchers that can be 
exchanged for goods or services of the service user’s choice, or privileges 
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 such as take-home methadone doses) contingent on each presentation of 
a drug-negative test (for example, free from cocaine or non-prescribed 
opioids). 
• The frequency of screening should be set at three tests per week for the 
first 3 weeks, two tests per week for the next 3 weeks, and one per week 
thereafter until stability is achieved.  
• If vouchers are used, they should have monetary values that start in the 
region of £2 and increase with each additional, continuous period of 
abstinence. 
• Urinalysis should be the preferred method of testing but oral fluid tests may 
be considered as an alternative.  
 
Contingency management to improve physical healthcare  
For people at risk of physical health problems (including transmittable 
diseases) resulting from their drug misuse, material incentives (for example, 
shopping vouchers of up to £10 in value) should be considered to encourage 
harm reduction. Incentives should be offered on a one-off basis or over a 
limited duration, contingent on concordance with or completion of each 
intervention, in particular for: 
• hepatitis B/C and HIV testing 
• hepatitis B immunisation  
• tuberculosis testing.  
 
Implementing contingency management 
Drug services should ensure that as part of the introduction of contingency 
management, staff are trained and competent in appropriate near-patient 
testing methods and in the delivery of contingency management.  
Contingency management should be introduced to drug services in the 
phased implementation programme led by the NTA, in which staff training and 
the development of service delivery systems are carefully evaluated. The 
outcome of this evaluation should be used to inform the full-scale 
implementation of contingency management. 
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1 Guidance 
The following guidance is based on the best available evidence. The full 
guideline (www.nice.org.uk/CG051fullguideline) gives details of the methods 
and the evidence used to develop the guidance (see section 5 for details). 
1.1 General considerations 
1.1.1 Care of people who misuse drugs 
1.1.1.1 To enable people who misuse drugs to make informed decisions 
about their treatment and care, staff should explain options for 
abstinence-oriented, maintenance-oriented and harm-reduction 
interventions at the person’s initial contact with services and at 
subsequent formal reviews. 
1.1.1.2 Staff should discuss with people who misuse drugs whether to 
involve their families and carers in their assessment and treatment 
plans. However, staff should ensure that the service user’s right to 
confidentiality is respected. 
1.1.1.3 In order to reduce loss of contact when people who misuse drugs 
transfer between services, staff should ensure that there are clear 
and agreed plans to facilitate effective transfer. 
1.1.1.4 All interventions for people who misuse drugs should be delivered 
by staff who are competent in delivering the intervention and who 
receive appropriate supervision. 
1.1.1.5 People who misuse drugs should be given the same care, respect 
and privacy as any other person.  
1.1.2 Supporting families and carers 
1.1.2.1 Staff should ask families and carers about, and discuss concerns 
regarding, the impact of drug misuse on themselves and other 
family members, including children. Staff should also: 
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 • offer family members and carers an assessment of their 
personal, social and mental health needs 
• provide verbal and written information and advice on the impact 
of drug misuse on service users, families and carers. 
1.1.2.2 Where the needs of families and carers of people who misuse 
drugs have been identified, staff should:  
• offer guided self-help, typically consisting of a single session 
with the provision of written material  
• provide information about, and facilitate contact with, support 
groups, such as self-help groups specifically focused on 
addressing families’ and carers’ needs. 
1.1.2.3 Where the families of people who misuse drugs have not benefited, 
or are not likely to benefit, from guided self-help and/or support 
groups and continue to have significant problems, staff should 
consider offering individual family meetings. These should: 
• provide information and education about drug misuse 
• help to identify sources of stress related to drug misuse 
• explore and promote effective coping behaviours 
• normally consist of at least five weekly sessions. 
1.2 Identification and assessment of drug misuse 
1.2.1 Asking questions about drug misuse 
1.2.1.1 Staff in mental health and criminal justice settings (in which drug 
misuse is known to be prevalent) should ask service users routinely 
about recent legal and illicit drug use. The questions should include 
whether they have used drugs and, if so:  
• of what type and method of administration 
• in what quantity 
• how frequently. 
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 1.2.1.2 In settings such as primary care, general hospitals and emergency 
departments, staff should consider asking people about recent drug 
use if they present with symptoms that suggest the possibility of 
drug misuse, for example: 
• acute chest pain in a young person 
• acute psychosis 
• mood and sleep disorders. 
1.2.2 Assessment 
1.2.2.1 When making an assessment and developing and agreeing a care 
plan, staff should consider the service user’s: 
• medical, psychological, social and occupational needs 
• history of drug use 
• experience of previous treatment, if any 
• goals in relation to his or her drug use  
• treatment preferences. 
1.2.2.2 Staff who are responsible for the delivery and monitoring of the 
agreed care plan should: 
• establish and sustain a respectful and supportive relationship 
with the service user  
• help the service user to identify situations or states when he or 
she is vulnerable to drug misuse and to explore alternative 
coping strategies 
• ensure that all service users have full access to a wide range of 
services 
• ensure that maintaining the service user’s engagement with 
services remains a major focus of the care plan 
• maintain effective collaboration with other care providers. 
1.2.2.3 Healthcare professionals should use biological testing (for example, 
of urine or oral fluid samples) as part of a comprehensive 
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 assessment of drug use, but they should not rely on it as the sole 
method of diagnosis and assessment.  
1.3 Brief interventions and self-help 
1.3.1 Brief interventions  
Brief interventions can be used opportunistically in a variety of settings for 
people not in contact with drug services (for example, in mental health, 
general health and social care settings, and emergency departments) and for 
people in limited contact with drug services (such as at needle and syringe 
exchanges, and community pharmacies).  
1.3.1.1 During routine contacts and opportunistically (for example, at 
needle and syringe exchanges), staff should provide information 
and advice to all people who misuse drugs about reducing 
exposure to blood-borne viruses. This should include advice on 
reducing sexual and injection risk behaviours. Staff should consider 
offering testing for blood-borne viruses. 
1.3.1.2 Group-based psychoeducational interventions that give information 
about reducing exposure to blood-borne viruses and/or about 
reducing sexual and injection risk behaviours for people who 
misuse drugs should not be routinely provided. 
1.3.1.3 Opportunistic brief interventions focused on motivation should be 
offered to people in limited contact with drug services (for example, 
those attending a needle and syringe exchange or primary care 
settings) if concerns about drug misuse are identified by the service 
user or staff member. These interventions should: 
• normally consist of two sessions each lasting 10–45 minutes 
• explore ambivalence about drug use and possible treatment, 
with the aim of increasing motivation to change behaviour, and 
provide non-judgemental feedback.  
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 1.3.1.4 Opportunistic brief interventions focused on motivation should be 
offered to people not in contact with drug services (for example, in 
primary or secondary care settings, occupational health or tertiary 
education) if concerns about drug misuse are identified by the 
person or staff member. These interventions should: 
• normally consist of two sessions each lasting 10–45 minutes  
• explore ambivalence about drug use and possible treatment, 
with the aim of increasing motivation to change behaviour, and 
provide non-judgemental feedback.  
1.3.2 Self-help 
1.3.2.1 Staff should routinely provide people who misuse drugs with 
information about self-help groups. These groups should normally 
be based on 12-step principles; for example, Narcotics Anonymous 
and Cocaine Anonymous. 
1.3.2.2 If a person who misuses drugs has expressed an interest in 
attending a 12-step self-help group, staff should consider facilitating 
the person’s initial contact with the group, for example by making 
the appointment, arranging transport, accompanying him or her to 
the first session and dealing with any concerns.  
1.4 Formal psychosocial interventions 
A range of psychosocial interventions are effective in the treatment of drug 
misuse; these include contingency management and behavioural couples 
therapy for drug-specific problems and a range of evidence-based 
psychological interventions, such as cognitive behavioural therapy, for 
common comorbid mental health problems.    
1.4.1 Contingency management  
Contingency management is a set of techniques that focus on changing 
specified behaviours. In drug misuse, it involves offering incentives for positive 
behaviours such as abstinence or a reduction in illicit drug use, and 
participation in health-promoting interventions. For example, an incentive is 
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 offered when a service user submits a biological sample that is negative for 
the specified drug(s). The emphasis on reinforcing positive behaviours is 
consistent with current knowledge about the underlying neuropsychology of 
many people who misuse drugs and is more likely to be effective than 
penalising negative behaviours. There is good evidence that contingency 
management increases the likelihood of positive behaviours and is cost 
effective. 
For contingency management to be effective, staff need to discuss with the 
service user what incentives are to be used so that these are perceived as 
reinforcing by those participating in the programme. Incentives need to be 
provided consistently and as soon as possible after the positive behaviour 
(such as submission of a drug-negative sample). Limited increases in the 
value of the incentive with successive periods of abstinence also appear to be 
effective. 
A variety of incentives have proved effective in contingency management 
programmes, including vouchers (which can be exchanged for goods or 
services of the service user’s choice), privileges (for example, take-home 
methadone doses) and modest financial incentives.  
For more information on contingency management, see appendix C. 
1.4.1.1 Drug services should introduce contingency management 
programmes – as part of the phased implementation programme 
led by the NTA – to reduce illicit drug use and/or promote 
engagement with services for people receiving methadone 
maintenance treatment. 
1.4.1.2 Drug services should introduce contingency management 
programmes – as part of the phased implementation programme 
led by the NTA – to reduce illicit drug use, promote abstinence 
and/or promote engagement with services for people who primarily 
misuse stimulants. 
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 1.4.1.3 Staff delivering contingency management programmes should 
ensure that: 
• the target is agreed in collaboration with the service user 
• the incentives are provided in a timely and consistent manner 
• the service user fully understands the relationship between the 
treatment goal and the incentive schedule 
• the incentive is perceived to be reinforcing and supports a 
healthy/drug-free lifestyle. 
1.4.1.4 Contingency management aimed at reducing illicit drug use for 
people receiving methadone maintenance treatment or who 
primarily misuse stimulants should be based on the following 
principles. 
• The programme should offer incentives (usually vouchers that 
can be exchanged for goods or services of the service user’s 
choice, or privileges such as take-home methadone doses) 
contingent on each presentation of a drug-negative test (for 
example, free from cocaine or non-prescribed opioids). 
• If vouchers are used, they should have monetary values that 
start in the region of £2 and increase with each additional, 
continuous period of abstinence. 
• The frequency of screening should be set at three tests per 
week for the first 3 weeks, two tests per week for the next 
3 weeks, and one per week thereafter until stability is achieved.  
• Urinalysis should be the preferred method of testing but oral fluid 
tests may be considered as an alternative.  
1.4.2 Contingency management to improve physical healthcare  
1.4.2.1 For people at risk of physical health problems (including 
transmittable diseases) resulting from their drug misuse, material 
incentives (for example, shopping vouchers of up to £10 in value) 
should be considered to encourage harm reduction. Incentives 
should be offered on a one-off basis or over a limited duration, 
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 contingent on concordance with or completion of each intervention, 
in particular for: 
• hepatitis B/C and HIV testing 
• hepatitis B immunisation  
• tuberculosis testing.  
1.4.3 Implementing contingency management 
The implementation of contingency management presents a significant 
challenge for current drug services, in particular with regard to staff training 
and service delivery systems. The following recommendations address these 
two issues (for further details please refer to appendix C). 
1.4.3.1 Drug services should ensure that as part of the introduction of 
contingency management, staff are trained and competent in 
appropriate near-patient testing methods and in the delivery of 
contingency management. 
1.4.3.2 Contingency management should be introduced to drug services in 
the phased implementation programme led by the NTA, in which 
staff training and the development of service delivery systems are 
carefully evaluated. The outcome of this evaluation should be used 
to inform the full-scale implementation of contingency 
management. 
1.4.4 Behavioural couples therapy 
1.4.4.1 Behavioural couples therapy should be considered for people who 
are in close contact with a non-drug-misusing partner and who 
present for treatment of stimulant or opioid misuse (including those 
who continue to use illicit drugs while receiving opioid maintenance 
treatment or after completing opioid detoxification). The intervention 
should:  
• focus on the service user’s drug misuse 
• consist of at least 12 weekly sessions.  
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 1.4.5 Interventions to improve concordance with naltrexone 
treatment 
Naltrexone is an opioid antagonist that eliminates the positive experiences 
associated with opioid use. It may provide some benefit in sustaining 
abstinence among people who have completed opioid detoxification. 
Psychosocial interventions can improve concordance with naltrexone 
treatment. 
1.4.5.1 For people receiving naltrexone maintenance treatment to help 
prevent relapse to opioid dependence, staff should consider 
offering: 
• contingency management to all service users (based on the 
principles described in recommendations 1.4.1.3 and 1.4.1.4)  
• behavioural couples therapy or behavioural family interventions 
to service users in close contact with a non-drug-misusing family 
member, carer or partner (based on the principles described in 
recommendation 1.4.3.1 for behavioural couples therapy). 
1.4.6 Cognitive behavioural therapy and psychodynamic 
therapy 
1.4.6.1 Cognitive behavioural therapy and psychodynamic therapy focused 
on the treatment of drug misuse should not be offered routinely to 
people presenting for treatment of cannabis or stimulant misuse or 
those receiving opioid maintenance treatment. 
1.4.6.2 Evidence-based psychological treatments (in particular, cognitive 
behavioural therapy) should be considered for the treatment of 
comorbid depression and anxiety disorders in line with existing 
NICE guidance (see section 6) for people who misuse cannabis or 
stimulants, and for those who have achieved abstinence or are 
stabilised on opioid maintenance treatment. 
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 1.5 Residential, prison and inpatient care 
1.5.1 Inpatient and residential settings 
1.5.1.1 The same range of psychosocial interventions should be available 
in inpatient and residential settings as in community settings. These 
should normally include contingency management, behavioural 
couples therapy and cognitive behavioural therapy. Services should 
encourage and facilitate participation in self-help groups. 
1.5.1.2 Residential treatment may be considered for people who are 
seeking abstinence and who have significant comorbid physical, 
mental health or social (for example, housing) problems. The 
person should have completed a residential or inpatient 
detoxification programme and have not benefited from previous 
community-based psychosocial treatment. 
1.5.1.3 People who have relapsed to opioid use during or after treatment in 
an inpatient or residential setting should be offered an urgent 
assessment. Offering prompt access to alternative community, 
residential or inpatient support, including maintenance treatment, 
should be considered. 
1.5.2 Criminal justice system 
1.5.2.1 For people who misuse drugs, access to and choice of treatment 
should be the same whether they participate in treatment 
voluntarily or are legally required to do so. 
1.5.2.2 For people in prison who have drug misuse problems, treatment 
options should be comparable to those available in the community. 
Healthcare professionals should take into account additional 
considerations specific to the prison setting, which include: 
• the length of sentence or remand period, and the possibility of 
unplanned release 
• risks of self-harm, death or post-release overdose.  
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 1.5.2.3 People in prison who have significant drug misuse problems may 
be considered for a therapeutic community developed for the 
specific purpose of treating drug misuse within the prison 
environment.  
1.5.2.4 For people who have made an informed decision to remain 
abstinent after release from prison, residential treatment should be 
considered as part of an overall care plan. 
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2 Notes on the scope of the guidance 
NICE guidelines are developed in accordance with a scope that defines what 
the guideline will and will not cover. The scope of this guideline is available 
from www.nice.org.uk/page.aspx?o=275101. 
This guideline covers psychosocial interventions for adults and young people 
who misuse opioids, cannabis or stimulants (for example, cocaine or 
amphetamine). The guideline will be of relevance to the NHS, in particular 
inpatient and specialist residential and community-based treatment settings, 
and related organisations, including prison services. Although the guideline 
may comment on the interface with other services, such as those provided by 
the voluntary sector, it will not provide specific recommendations directed 
solely at non-NHS services, except in so far as they are provided under 
contract to the NHS. 
The guideline does not specifically cover: 
• people with dual diagnoses 
• people who misuse alcohol, prescription drugs or solvents 
• diagnosis or primary prevention 
• people younger than 16 years. 
How this guideline was developed 
NICE commissioned the National Collaborating Centre for Mental Health to 
develop this guideline. The Centre established a Guideline Development 
Group (see appendix A), which reviewed the evidence and developed the 
recommendations. An independent Guideline Review Panel oversaw the 
development of the guideline (see appendix B). 
There is more information in the booklet: ‘The guideline development process: 
an overview for stakeholders, the public and the NHS’ (third edition, published 
April 2007), which is available from www.nice.org.uk/guidelinesprocess or by 
telephoning 0870 1555 455 (quote reference N1233). 
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 3 Implementation  
The Healthcare Commission assesses the performance of NHS organisations 
in meeting core and developmental standards set by the Department of Health 
in ‘Standards for better health’, issued in July 2004. Implementation of clinical 
guidelines forms part of the developmental standard D2. Core standard C5 
says that national agreed guidance should be taken into account when NHS 
organisations are planning and delivering care. 
NICE has developed tools (listed below) to help organisations implement the 
recommendations in this guideline as well as those in ‘Drug misuse: opioid 
detoxification’. These tools are available on our website 
(www.nice.org.uk/CG051). The tools for these guidelines have been 
integrated with tools for other NICE guidance on drug misuse.  
• An information briefing, which explains the implementation support 
available and contains links to relevant tools/documents.  
• Slides highlighting key messages for local discussion. 
• Costing tools 
− costing report to estimate the national savings and costs associated with 
implementation. 
− costing template to estimate the local costs and savings involved. 
• Audit criteria to monitor local practice. 
4 Research recommendations 
The Guideline Development Group has made the following recommendations 
for research, based on its review of evidence, to improve NICE guidance and 
care of service users in the future.  
4.1 Implementation of contingency management  
Which methods of implementing contingency management (including 
delivering and stopping incentives) and which settings (including legally 
coerced, community-based and residential) – compared with one another and 
with standard care – are associated with the longest periods of continued 
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 abstinence and reduced drug misuse, and with maintenance of 
abstinence/reduction of drug misuse at follow-up?  
Why this is important 
Although the efficacy of contingency management for drug misuse has been 
extensively investigated, there is a lack of large-scale and well-conducted 
implementation studies. The implementation of contingency management 
programmes in the UK would be aided by research assessing specific 
components of the programme.  
4.2 Testing within contingency management 
programmes 
For people who misuse drugs and who are participating in contingency 
management, which method of testing – urinalysis, sweat analysis or oral fluid 
analysis – is most sensitive, specific, cost effective and acceptable to service 
users?  
Why this is important 
There is a lack of data comparing the sensitivity and specificity, cost 
effectiveness and acceptability to service users of these methods of testing. 
Identifying drug use during treatment is an important aspect of contingency 
management; identifying which testing methods are the most effective is 
important for health and social care services intending to implement 
contingency management programmes. 
4.3 Psychosocial interventions within needle and syringe 
exchange programmes 
For people who inject drugs, do needle and syringe exchange programmes 
with a greater psychosocial content reduce injection and sexual risk 
behaviours and rates of seroprevalence of blood-borne virus infection more 
than programmes with minimal psychosocial content? Examples of greater 
psychosocial content include distribution of syringes and needles by staff 
and/or provision of psychoeducation on reducing the risk of blood-borne 
viruses. Examples of minimal psychosocial content include machine 
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 dispensing of syringes and needles and provision of minimal or no information 
on reducing blood-borne virus risk. 
Why this is important 
There is extensive literature assessing whether needle and syringe exchange 
programmes reduce injection and sexual risk behaviours and HIV 
seroprevalence rates. However, there is very little research that seeks to 
distinguish the impact of the provision of sterile needles from that of the 
psychosocial interventions often offered within such programmes. 
Psychosocial contact and interventions require substantial resources; 
therefore it is important to assess whether these additional elements are 
clinically and cost effective.  
4.4 Residential treatment 
Is residential treatment associated with higher rates of abstinence or reduction 
in drug misuse than community-based care?  
Why this is important 
There have been some studies comparing residential treatment with 
community-based treatment. However, these studies are often based on small 
sample sizes, lack methodological quality and have produced inconsistent 
results. Residential treatment requires significantly more resources than 
community-based treatment, so it is important to assess whether residential 
treatment is more effective. 
5 Other versions of this guideline 
5.1 Full guideline 
The full guideline, ‘Drug misuse: psychosocial interventions’, contains details 
of the methods and evidence used to develop the guideline. It is published by 
the National Collaborating Centre for Mental Health, and is available from 
www.nccmh.org.uk, our website (www.nice.org.uk/CG051fullguideline) and 
the National Library for Health (www.nlh.nhs.uk).  
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 5.2 Quick reference guide 
A quick reference guide for healthcare professionals is also available from 
www.nice.org/CG051quickrefguide 
For printed copies, phone the NHS Response Line on 0870 1555 455 (quote 
reference number N1289). 
5.3 ‘Understanding NICE guidance’  
Information for people who misuse drugs and their carers (‘Understanding 
NICE guidance’) is available from www.nice.org.uk/CG051publicinfo 
For printed copies, phone the NHS Response Line on 0870 1555 455 (quote 
reference number N1290).  
6 Related NICE guidance 
Drug misuse: opioid detoxification. NICE clinical guideline 52 (2007). Available 
from www.nice.org.uk/CG052 
Community-based interventions to reduce substance misuse among 
vulnerable and disadvantaged children and young people. NICE public health 
intervention guidance 4 (2007). Available from www.nice.org.uk/PHI004
Methadone and buprenorphine for the management of opioid dependence. 
NICE technology appraisal guidance 114 (2007). Available from 
www.nice.org.uk/TA114
Naltrexone for the management of opioid dependence. NICE technology 
appraisal guidance 115 (2007). Available from www.nice.org.uk/TA115
Obsessive–compulsive disorder: core interventions in the treatment of 
obsessive–compulsive disorder and body dysmorphic disorder. NICE clinical 
guideline 31 (2005). Available from www.nice.org.uk/CG031  
Post-traumatic stress disorder (PTSD): the management of PTSD in adults 
and children in primary and secondary care. NICE clinical guideline 26 (2005). 
Available from www.nice.org.uk/CG026
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 Depression (amended): management of depression in primary and secondary 
care. NICE clinical guideline 23 (amended) (2004, amended 2007). Available 
from www.nice.org.uk/CG023
Anxiety (amended): management of anxiety (panic disorder, with or without 
agoraphobia, and generalised anxiety disorder) in adults in primary, 
secondary and community care. NICE clinical guideline 22 (amended) (2004, 
amended 2007). Available from www.nice.org.uk/CG022  
Self-harm: the short-term physical and psychological management and 
secondary prevention of self-harm in primary and secondary care. NICE 
clinical guideline 16 (2004). Available from www.nice.org.uk/CG016
Eating disorders: core interventions in the treatment and management of 
anorexia nervosa, bulimia nervosa and related eating disorders. NICE clinical 
guideline 9 (2004). Available from www.nice.org.uk/CG009
 
7 Updating the guideline 
NICE clinical guidelines are updated as needed so that recommendations 
take into account important new information. We check for new evidence 2 
and 4 years after publication, to decide whether all or part of the guideline 
should be updated. If important new evidence is published at other times, we 
may decide to do a more rapid update of some recommendations.  
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 Appendix C: Contingency management – key 
elements in the delivery of a programme 
The introduction of contingency management into drug misuse services in the 
NHS presents a considerable challenge. This is primarily because 
contingency management has not been widely used in the NHS; hence staff 
are not trained in the technique and a major training programme will be 
required to implement it. Another challenge is address the concerns of staff, 
service users and the wider public about contingency management, in 
particular concerns that: 
• the intervention may ‘reward’ illicit drug use  
• the effects will not be maintained in the long term 
• the system is open to abuse as people may ‘cheat’ their drug tests 
• incentive-based systems will not work outside the healthcare system (that 
of the United States) in which they were developed. 
 
The aim of this appendix, firstly, is to provide a brief introduction to 
contingency management for those not familiar with this intervention. 
Secondly, it will address the issues outlined above by setting out a possible 
strategy for implementation in the NHS, drawing on an evidence base from 
the United States, Europe and Australia.  
Introduction to contingency management 
Contingency management refers to a set of techniques that focus on the 
reinforcement of certain specified behaviours. These may include abstinence 
from drugs (for example, cocaine), reduction in drug misuse (for example, 
illicit drug use by people receiving methadone maintenance treatment), and 
promoting adherence to interventions that can improve physical health 
outcomes (for example, attending for hepatitis C tests) (Petry, 2006). To date, 
over 25 trials of contingency management have been conducted, involving 
over 5000 participants, which constitute the largest single body of evidence for 
the effectiveness of psychosocial interventions in drug misuse. In the formal 
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 studies of contingency management, incentives have included vouchers 
(exchangeable for goods such as food), cash rewards (of low monetary 
value), prizes (including cash and goods) and clinic privileges (such as non-
supervised consumption). All the incentives have been shown to be effective, 
although it was the view of the guideline development group that vouchers 
and clinic privileges would generally be more easily implemented in the NHS.  
The following principles underlie the effective delivery of contingency 
management (Petry 2006).  
• Robust, routine testing for drug misuse should be carried out. 
• Targets should be agreed in collaboration with the service user. 
• Incentives should be provided in a timely and consistent manner. 
• The relationship between the treatment goal and the incentive schedule 
should be understood by the service user 
• Incentives should be perceived by the service user to be reinforcing and to 
support a healthy/drug-free lifestyle. 
 
Implementing contingency management in the NHS 
Although contingency management has not yet been implemented in the NHS 
(but see McQuaid et al. 2007 for a report of a pilot study), there have been a 
number of major studies looking at its uptake in the United States, Europe and 
Australia. Crucially, these studies give an account of its implementation in 
services where initially there was considerable resistance on the part of both 
staff and people who misuse drugs. They report positive shifts in staff 
attitudes as the understanding of contingency management increased and its 
beneficial impact on the lives of people who misuse drugs became apparent 
(McGovern et al. 2004; Kellogg et al. 2005; Kirby et al. 2006; Ritter and 
Cameron 2007).  
Studies have also looked at the organisational development required to 
support successful implementation. Kellogg et al. (2005) identified, in addition 
to the principles outlined above, four key aspects of the uptake of contingency 
management in the public healthcare system in New York:  
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 • endorsement of the programme by senior managers and clinicians, and 
their engagement with the concerns of direct care staff  
• provision of a comprehensive education and training programme that 
provided clear direction for staff, many of whom were unfamiliar with the 
basic principles of contingency management 
• recognition by staff that contingency management is an intervention aimed 
at changing specific key behaviours, and does not simply reward people for 
general good behaviour 
• a shift in the focus of the service to one that is incentive-orientated, where 
contingency management plays a central role in promoting a positive 
relationship between staff and service users.1  
 
In a series of interviews and discussions with staff and service users, Kellogg 
et al. (2005) found that contingency management increased the motivation of 
service users to undergo treatment, facilitated therapeutic progress, increased 
staff optimism about treatment outcomes and their morale, and promoted the 
development of more positive relationships both between service users and 
staff and among staff members. As a result, there was a shift from viewing 
contingency management as an intervention that would be difficult to integrate 
with other interventions to it becoming the main focus of interventions with 
service users. Other studies (for example, Higgins et al. 2000) also provide 
important advice on how the effects of interventions can be maintained once 
incentives are discontinued.  
In the NHS, several other factors will need to be considered when developing 
an implementation programme. These may include:  
• the integration, where appropriate, of contingency management with the 
keyworking responsibilities of staff 
                                                 
1 The emphasis on incentives is consistent with current knowledge about the underlying 
neuropsychology of many people who misuse drugs; specifically that people with antisocial 
personality disorder (ASPD) (who account for a significant proportion of long-term drug users) 
are much more likely to respond to positive than to punitive approaches. Messina et al. (2003) 
found that people with ASPD who received contingency management were more likely to 
abstain from cocaine use than both participants without ASPD receiving contingency 
management or cognitive behavioural therapy and participants with ASPD receiving cognitive 
behavioural therapy.  
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 • the identification of those groups of people who misuse drugs who are most 
likely to benefit from contingency management (for example, it might be 
expected that about 30% of people receiving methadone maintenance 
treatment will be considered for contingency management) 
• the development of near-patient testing 
• the impact on service-user government benefits.   
The implementation process 
Where possible, implementation in the NHS should draw on the experience so 
far (albeit limited) of contingency management in the NHS and on the 
experience of agencies such as the National Treatment Agency for Substance 
Misuse (NTA) in the implementation of service developments in drug misuse. 
The NTA, with its lead role in drug misuse, is best placed to lead an 
implementation programme, as it has both the national and regional 
infrastructure and the experience (for example, through its work on the 
International Treatment Effectiveness Project). Any implementation 
programme should include the following elements:  
• the establishment of a series of demonstration sites  
• dissemination of the findings, including those emerging from demonstration 
sites, to inform the field 
• an agreement with local commissioners where change of contracts or 
service level agreements are required 
• a review of service readiness to implement contingency management and 
the involvement of senior management, clinicians and key workers in any 
required service developments 
• training programmes for staff to enable them to deliver contingency 
management  
• working with service users to raise awareness about contingency 
management and involve them in local service design 
• evaluation of the implementation programme. 
 
The provision of training to deliver contingency management may include a 
requirement for service managers, supervisors and front-line staff to 
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 acknowledge the need for institutional change and staff ‘buy in’. Training could 
be designed to provide a foundation covering the theory, practice and 
research findings of contingency management, including the factors 
associated with its successful implementation (Kellogg et al. 2005). A major 
focus of the training programme will be on identifying and developing staff 
competencies to deliver contingency management in a manner that 
emphasises the positive, reinforcing aspects of the intervention.  
The structure of any evaluation of contingency management could follow that 
of the implementation programme and may examine the following issues 
using quantitative and qualitative methods:  
• service design (the feasibility of establishing contingency management in 
services, structures associated with effective uptake and barriers to uptake)  
• the most effective training models associated with sustained uptake 
• the experiences of staff and service users.  
 
Conclusion 
This appendix sets out the background and process by which contingency 
management may be implemented in drug misuse services in the NHS. 
Successful implementation of contingency management will have 
considerable benefits for people who misuse drugs, their families and wider 
society.  
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